Inhaled adrenergics and anticholinergics in obstructive lung disease: Do they enhance mucociliary clearance?

Respiratory Care

Volumn 52, Issue 9, 2007, Pages 1159-1173

  Restrepol, Ruben D ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adrenergic; Airway clearance; Anticholinergic; Bronchodilator; Chronic obstructive pulmonary disease mucociliary clearance; Mucus; Obstructive lung disease; Sputum

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; ISOPRENALINE; LEVALBUTEROL; MUCOLYTIC AGENT; OXITROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; SCOPOLAMINE BROMIDE; TERBUTALINE; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ADRENERGIC NERVE; ASTHMA; BRONCHIECTASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; LUNG FUNCTION; MUCOCILIARY CLEARANCE; MUCUS SECRETION; NONHUMAN; PARASYMPATHETIC INNERVATION; PATHOPHYSIOLOGY; UNSPECIFIED SIDE EFFECT; BRONCHUS; INHALATIONAL DRUG ADMINISTRATION; MUCUS; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; REVIEW; SECRETION;

ADMINISTRATION, INHALATION; ADRENERGIC AGENTS; BRONCHI; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; MUCOCILIARY CLEARANCE; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA;

EID: 38449083847     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (148)

1. Rubin BK. Physiology of airway mucus clearance. Respir Care 2002;47(7):761-768.
2. Antunes MB, Cohen NA. Mucociliary clearance-a critical upper airway host defense mechanism amd meuiods of assessment. Curr Opin Allergy Clin Immunol 2007;7(1):5-10.
3. Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996;154(6 Pt 1):1868-1902.
4. Rubin BK. The pharmacologic approach to airway clearance: mu-coactive agents. Respir Care 2002;47(7):818-822.
5. King M, Rubin BK. Pharmacological approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev 2002; 54(11):1475-1490.
6. Rogers DF. The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. COPD 2005; 2(3):341-353.
7. King M. Role of mucus viscoelasticity in cough clearance. Biorheology 1987;24(6):589-597.
8. Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during a pulmonary exacerbation. Am J Respir Crit Care Med 2007;175(8):816-821.
9. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004;31(1):86-91.
10. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007;8(1):24-29.
11. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006:38(2): 116-125.
12. Lopez-Vidriero MT, Reid L. Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases. Am Rev Respir Dis 1978;117(3):465-177.
13. Charman J, Reid L. Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology 1972;9(3):185-199.
14. Shimura S, Sasaki T, Sasaki H, Takishima T, Umeya K. Viscoelastic properties of bronchorrhoea sputum in bronchial asthmatics. Biorheology 1988;25(l-2): 173-179.
15. Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol 2004:4(3) :241-250.
16. Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995:13(6):748-756.
17. Hogg JC. Pathology of asthma. J Allergy Clin Immunol 1993;92(1 Pt 1):l-5.
18. Kuyper LM, Paré PD, Hogg JC, Lambert RK, Ionescu D, Woods R, Bai TR. Characterization of airway plugging in fatal asthma. Am J Med 2003;115(1):6-ll.
19. Rubin BK, Tomkiewicz R, Fahy JV, Green FH. Histopathology of fatal asthma: drowning in mucus. Pediatr Pulmonol 2001:Suppl 23:88S-89S.
20. Dicpinigaitis PV. Cough. 4: Cough in asthma and eosinophilic bronchitis. Thorax 2004;59(1):71-72.
21. Rogers DF. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 2005:18(1): 1-8.
22. Bennett WD. Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002:110(6 Suppl):S291-S297.
23. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994; 49(6):545-548.
24. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002;2(3):249-255.
25. Miyata T. Novel approach to respiratory pharmacology: pharmacological basis of cough, sputum and airway clearance. Yakugaku Zasshi 2003;123(12):987-1006.
26. Sabater JR, Lee TA, Abraham WM. Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep. Chest 2005;128(5):3743-3749.
27. Fischer BM, Voynow JA. Neutrophil elastase induces MUC5AC gene expression in airway epithelium via a pathway involving reactive oxygen species. Am J Respir Cell Mol Biol 2002;26(4):447-452.
28. Nadel JA. Role of mast cell and neutrophil proteases in airway secretion. Am Rev Respir Dis 1991;144(3 Pt 2):S48-S51.
29. Amitani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, et al. Effect of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991;4(1):26-32.
30. Smallman LA, Hill SL, Stockey RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine protease effect. Thorax 1984;39(9):663-667.
31. +-transport. Am J Physiol: Lung Cell Mol Physiol 2005:288(5): L813-L819.
32. O'Riordan TG, Otero R, Mao YM, Lauredo I, Abraham WM. Elastase contributes to antigen-induced mucociliary dysfunction in ovine ail-ways. Am J Respir Crit Care Med 1997;155(5):1522-1528.
33. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160(3):893-898.
34. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160(5 Pt 1):1532-1539.
35. Little SA, MacLeod KJ, Chalmers GW, Love JG, McSharry C, Thomson NC. Am J Med 2002;112(6):446-452.
36. Conese M, Copreni E, Di Gioia S, De Rinaldis P, Fumarulo R. Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease. J Cyst Fibrosis 2003;2(3):129-135.
37. Qiu Y. Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168(8):968-975.
38. Kim JS, Okamoto K, Arima S, Rubin BK. Vasoactive intestinal peptide stimulates mucus secretion, but nitric oxide has no effect on mucus secretion in the ferret trachea. J Appl Physiol 2006;101(2): 486-491.
39. Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol 2006;101(3):971-985.
40. 2 muscarinic receptor. Trends Pharmacol Sci 1998; 19(8): 322-327.
41. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117(Suppl 12A):24S-32S.
42. Gross NJ, Barnes PJ. A short tour around the muscarinic receptor. Am Rev Respir Dis 1988;138(4):765-767.
43. 3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990;3(1):47-351.
44. Lefkowitz RJ, Hoffman BB, Taylor P. Neurohormonal transmission: the autonomic and somatic motor nervous system. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Oilman's the pharmacological basis of therapeutics, 8th ed. Elmsford, NY: Pergamon Press Inc; 1990:84-121.
45. Disse B, Raichl R, Speck GA, Travnecker W, Rominger KL, Hammer R. Ba 679 BR, a novel anticholinergic bronchodilator. Life Sci 1993;52(5-6):537-544.
46. Witek TJ. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir Care 2000;45(7):826-830.
47. Joos GF. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch Chest Dis 2000;55(5):411-414.
48. Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev 1992;72(3):699-729.
49. Ayala LE, Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest 1989;96(6):1285-1291.
50. 2-muscarinic receptors on pulmonary parasympathetic nerves in the guinea pig. Br J Pharmacol 1991;102(1):267-271.
51. 2 muscarinic receptors in the lungs. Life Sci 1993;52(5-6):529-536.
52. 2 muscarinic receptor dysfunction. Am J Respir Crit Care Med 2003;167(4):550-556.
53. Diamond L, Altiere RJ, Thompson DC. The airway nonadrenergic, noncholinergic inhibitory nervous system. Chest 1988;93(6):1283-1285.
54. Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol 2001;125(1-2):129-144.
55. Joo NS, Irokawa T, Wu JV, Robbins RC, Whyte RI, Wine JJ. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem 2002;277(52):50710-50715.
56. Ollerenshaw S, Jarvis D, Woolcock A, Sullivan C, Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med 1989;320(19):1244-1248.
57. Lucchini RE, Facchini F, Turato G, Saetta M, Caramon G, Ciaccia A, et al. Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am J Respir Crit Care Med 1997;156(6):1963-1968.
58. Richardson J, Béland J. Nonadrenergic inhibitory nervous system in human airways. J Appl Physiol 1976;41(5 Pt 1):764-771.
59. Mossberg B, Strandberg K, Philipson K, Camner P. Tracheobronchial clearance in bronchial asthma: response to beta-adrenoceptor stimulation. Scand J Respir Dis 1976;57(3):119-128.
60. Isawa T, Teshima T, Hirano T, Ebina A, Anazawa Y, Konno K. Effect of bronchodilation on the deposition and clearance of radioaerosol in bronchial asthma in remission. J Nucl Med 1987;28(12):1901-1906.
61. Isawa T, Teshima T, Hirano T, Anazawa Y, Miki M, Konno K, Motomiya M. Does a beta 2-stimulator really facilitate mucociliary transport in the human lungs in vivo? A study with procaterol. Am Rev Respir Dis 1990;141(3):715-720.
62. Bateman IR, Pavia D, Sheahan NF, Newman SP, Clarke SW. Effects of terbutaline sulphate aerosol on bronchodilator response and lung mucociliary clearance in patients with mild stable asthma. Br J Clin Pharmacol 1983;15(6):695-700.
63. Mortensen I, Groth S, Lange P, Hermansen F. Effect of terbutaline on mucociliary clearance in asthmatic and healthy subjects after inhalation from a pressurised inhaler and a dry powder inhaler. Thorax 1991;46(11):817-823.
64. Mortensen I, Lange P, Nyboe J, Groth S. Lung mucociliary clearance. Eur I Nucl Med 1994;21(9):953-961.
65. Di Benedetto G, Manara-Shediac FS, Mehta A. Effect of cyclic AMP on ciliary activity of human respiratory epithelium. Eur Respir J 1991;4(7):789-795.
66. 2+ and cAMP. Am J Physiol 1992;263(2Pt 1):L232-L242.
67. Van As A. The role of selective β2-adrenoceptor stimulants in the control of ciliary activity. Respiration 1974;31(2):146-151.
68. Devalia JL, Sapsford RI, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells in-vitro. Pulm Pharmacol 1992;5(4):257-263.
69. Verdugo P, Johnson NT, Tarn PY. beta-adrenergic stimulation of respiratory ciliary activity. J Appl Physiol 1980;48(5):868-871.
70. Sanderson MJ, Dirksen ER. Mechanosensitive and beta-adrenergic control of the ciliary beat frequency of mammalian respiratory tract cells in culture. Am Rev Respir Dis 1989;139(2):432-140.
71. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Ped Respire Rev 2006;7(Suppl 1):S215-S219.
72. Widdicombe JH, Bastacky SJ, Wu DX-Y, Lee CY. Regulation of depth and composition of airway surface liquid. Eur Respir J 1997;10(12):2892-2897.
73. Webber SE, Widdicombe JG. The actions of methacholine, phenylephrine, salbutamol and histamine on mucus secretion from the ferret invitro trachea. Agents Actions 1987;22(l-2):82-85.
74. Piatti G, Ambrosetti U, Santus P, Allegra L. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharm Res 2005;51(2): 165-168.
75. Bennett WD, Zeman KL, Foy C, Shaffer C, lohnson F, Regnis J, et al. Effect of aerosolized INS316 on mucociliary clearance in mild chronic bronchitis. Am J Respir- Crit Care Med 2001;164(2):302-306.
76. Phipps RI, Williams IP, Richardson PS, Pell J, Pack RJ, Wright N. Sympathomimetic drugs stimulate the output of secretory glycoproteins from human bronchi in vitro. Clin Sci Lond 1982;63(1):23-28.
77. Leikauf GD, Ueki IF, Nadel JA. Autonomic regulation of viscoelasticity of cat tracheal gland secretions. J Appl Physiol 1984;56(2):426-430.
78. 2 agonists. Respirology 2005;10(4):426-435.
79. Peatfield AC, Richardson PS. The control of mucin secretion into the lumen of the cat trachea by α- and β-adrenoceptors, and their relative involvement during sympathetic nerve stimulation. Eur J Pharm 1982;81(4):617-626.
80. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI). A randomized placebo-controlled clinical trial. Am J Respir- Crit Care Med 2005;173(3):281-287.
81. Broadley KJ. Beta-adrenoceptor responses of the air-ways: for better or worse? Eur J Pharmacol 2006;533(l-3):15-27.
82. Camner P, Strandberg K, Philipson K. Increased mucociliary transport by adrenergic stimulation. Arch Environ Health 1976;31(2):79-82.
83. Sutton PP, Gemmell HG, Innes N, Davidson I, Smith FW, Legge JS, et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax 1988;43(1):57-60.
84. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in seudohypoaldosteronism. N Engl J Med 1999;341(3):156-162.
85. + across the trachea of the dog. Am Rev Respir- Dis 1979;120(3):547-552.
86. Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH, Seale JP. Effects of terbutaline in combination with mannitol on mucociliary clearance. Eur Respir-J 2002;20(6):1423-1429.
87. Jones R, Reid L. β-agonists and secretory cell number and intracellular glycoprotein in airway epithelium. Am J Pathol 1979;95(2):407-422.
88. Guleria R, Singh TR, Sinha S, Padhy K, Gupta K, Pande JN. Effect of single inhalation of a salbutamol, ipratropium bromide and beclomethasone on mucociliary clearance in patients with chronic obstructive airway disease. Indian J Chest Dis Allied Sci 2003;45(4):241-246.
89. Guleria R, Singh TR, Sinha S, Padhy AK, Gupta K, Pande JN. Effect of inhalation of salbutamol, beclomethasone dipropionate & ipratropium bromide on mucociliary clearance in some patients with chronic stable bronchial asthma. Indian J Med Res 2003:117:158-163.
90. Laube BL, Karmazyn YJ, Orens JB, Mogayzel PJ. Albuterol improves impaired mucociliary clearance after lung transplantation. J Heart Lung Transplant 2007;26(2):138-144.
91. Frohock JI, Wijkstrom-Frei C, Salathe M. Effects of albuterol enantiomers on ciliary beat frequency in ovine tracheal epithelial cells. J Appl Physiol 2002;92(6):2396-2402.
92. O'Riordan TG, Mao W, Palmer LB, Chen JJ. Assessing the effects of racemic and single-enantiomer albuterol on airway secretions in long-term intubated patients. Chest 2006;129(1):124-132.
93. Cleary JC, Karmazyn Y, Mogayzel PJ, Laube BL. Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects. Pulm Pharmacol Ther 2007 Jan 25;[Epubahead of print].
94. Wong LB, Miller IF, Yeates DB. Stimulation of ciliary beat frequency by autonomic agonists: in vivo. J Appl Physiol 1988;65(2):971-981.
95. Moretti M, Lopez-Vidriero MT, Pavia D, Clarke SW. Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis. Thorax 1997;52(2):176-180.
96. Weich DJ, Viljoen H, Sweetlove MA, Pretorius PH, van Rensburg AJ, Lotter MG, et al. Investigation into the effect of Fenoterol on mucociliary clearance in patients with chronic bronchitis. Eur J Nucl Med 1988;14(11):533-537.
97. Pavia D, Bateman JR, Sheahan NF, Clarke SW. Clearance of lung secretions in patients with chronic bronchitis: effect of terbutaline and ipratropium bromide aerosols. Eur J Respir Dis 1980;61(5):245-253.
98. Sadoul P, Puchelle E, Zahm JM, Jacquot J, Aug F, Polu JM. Effect of terbutaline on mucociliary transport and sputum properties in chronic bronchitis. Chest 1981;80(6 Suppl):885S-943S.
99. Matthys H, Daikeler G, Krauss B, Vastag E. Action of tulobuterol and fenoterol on the mucociliary clearance. Respiration 1987;51(2):105-112.
100. Weiss T, Dorow P, Felix R. Effects of a beta adrenergic drug and a secretolytic agent on regional mucociliary clearance in patients with COLD. Chest 1981;80(6 Suppl):881S-884S.
101. Bennett WD, Almond MA, Zeman KL, Johnson JG, Donohue JF. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther 2006;19(2):96-100.
102. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir- Crit Care Med 2005;172(12):1497-1504.
103. Hasani A, Toms N, O'Connor J, Dilworth JP, Agnew JE. Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma. Respir Med 2003;97(6):667-671.
104. Johnson C, Butler S, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis. Chest 2003;123(1):20-27.
105. Le Roux P, Le Luyer B. Inhaled bronchodilators and mucolytic agents in cystic fibrosis. Arch Pediatr 2003;10(Suppl 2):358S-363S.
106. Colombo JL. Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med 2003;9(6):504-508.
107. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002;34(4):287-296.
108. Zach MS, Oberwalder B, Forche G, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 1985;131(4):537-543.
109. Balfour-Lynn IM, Elbom JS. "CF asthma": what is it and what do we do about it? Thorax 2002;57(8):742-748.
110. 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway. J Biol Chem 2003;278(19):17320-17327.
111. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79(1 Suppl):S23-S45.
112. 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993;103(3):805-811.
113. Melloni B, Germouty J. [The influence of a new beta agonist (formoterol) on mucociliary function.] Rev Mal Respir 1992;9(5):503-507. (article in French)
114. Maneechotesuwan K, Essilfie-Quaye S, Meah S, Kelly C, Kharitonov SA, Adcock IM, Barnes PJ. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005;128(4):1936-1942.
115. Pavia D, Thomson ML. Inhibition of mucociliary clearance from the human lung by hyoscine. Lancet 1971:l(7696):449-450.
116. Annis P, Landa J, Lichtiger M. Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anesthesiology 1976;44(1):74-77.
117. Ramnarine SI, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol 1996;494(Pt 2):577-586.
118. Ishihara H, Shimura S, Satoh M, Masuda T, Nonaka H, Kase H, et al. Muscarinic receptor subtypes in feline tracheal submucosal gland secretion. Am J Physiol 1992;262(2 Pt 1):223L-228L.
119. Rogers DF. Muscarinic control of airway mucus secretion. In: Zaagsma J, Meurs H, Roffel AF, editors. Muscarinic receptors in airways diseases, Basel: Birkhauser Verlag, 2001;175-201.
120. Sturgess J, Reid L. An organ culture study of the effect of drugs on the secretory activity of the human bronchial submucosal gland. Clin Sci 1972;43(4):533-543.
121. Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986;81(5A):23S-27S.
122. Francis RA, Thomson ML, Pavia D, Douglas RB. Ipratropium bromide: mucociliary clearance rate and airway resistance in normal subjects. Br J Dis Chest 1977;71(3):173-178.
123. Foster WM, Langenback EG, Glaser ML, Bergofsky EH. Acute effect of ipratropium bromide at therapeutic dose on mucus transport of adult asthmatics. Eur J Respir Dis 1983;128(Pt 2):554-557.
124. Ruffin RE, Wolff RK, Dolovich MB, Rossman CM, Fitzgerald JD, Newhouse MT. Aerosol therapy with Sch 1000: short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. Chest 1978;73(4):501-506.
125. Pavia D, Bateman JR, Sheahan NF, Clarke SW. Effect of ipratropium bromide on mucociliary clearance and pulmonary function in reversible airways obstruction. Thorax 1979;34(4):501-507.
126. Taylor RG, Pavia D, Agnew JE, Lopez-Vidriero MT, Newman SP, Lennard-Jones T, et al. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986:41(4):295-300.
127. Bennett WD, Chapman WF, Mascarella JM. The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest 1993;103(2):488-495.
128. Chervinsky P. Double-blind study of ipratropium bromide, a new anticholinergic bronchodilator. J Allergy Clin Immunol 1977;59(1):22-30.
129. Miyata T, Matsumoto N, Yuki H, Oda Y, Takahama K, Kai H. Effects of anticholinergic bronchodilators on mucociliary transport and airway secretion. Jpn J Pharmacol 1989;51(1):11-15.
130. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154(4 Pt 1):876-880.
131. Barnes PJ. Tiotropium bromide. Epert Opin Invest Drags 2001;10(4):733-740.
132. 3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45(5):899-907.
133. Hasani A, Toms N, Agnew JE, Samo M, Harrison AJ, Dilworth P. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125(5): 1726-1734.
134. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004;3(4):247-268.
135. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guineapig and human airways. Br J Pharmacol 2006;148(3):291-298.
136. Pahl A, Bauhofer A, Petzold U, Cnota PJ, Maus J, Brune K, Szelenyi S. Synergistic effects of the anti-cholinergic R,R-glycopyrrolate with anti-inflammatory drugs. Biochem Pharmacol 2006;72(12):1690-1696.
137. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Bames PJ. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128(4): 1974-1979.
138. Schroeckenstein DC, Bush RK, Chervinsky P, Busse WW. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol 1988;82(1):115-119.
139. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. Ann Emerg Med 1994;23(2):270-274.
140. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995;25(4):470-473.
141. 3 (submandibular gland) muscarinic receptor subtypes in the rat. Br J Anaesth 1995;74(5):549-552.
142. Kompanje EJ. 'Death rattle' after withdrawal of mechanical ventilation: practical and ethical considerations. Intensive Crit Care Nurs 2006;22(4):214-219.
143. Hugel H, EUershaw J, Gambles M. Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med 2006;9(2):279-284.
144. Back IN, Jenkins K, Blower A, Beckhelling J. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med 2001;15(4):329-336.
145. Lawrey H. Hyoscine vs glycopyrronium for drying respiratory secretions in dying patients. Br J Community Nurs 2005;10(9):421-424.
146. Barnes PJ, Basbaum CB. Mapping of adrenergic receptors in the trachea by autoradiography. Exp Lung Res 1983;5(3):183-192.
147. Culpitt SV, Rogers DF, Traves SL, Bames PJ, Donnelly LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005;99(6):703-710.
148. 2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med